Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06136962
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Untreated Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06136910
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
Not yet recruiting
- Conditions
- Endometrial Neoplasms
- Interventions
- Diagnostic Test: next generation sequencing AND Immunohistochemical examination
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 350
- Registration Number
- NCT06126393
- Locations
- 🇨🇳
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
Not yet recruiting
- Conditions
- Risk FactorDistant MetastasisCervical CancerRadiotherapyPrognostic Model
- Interventions
- Radiation: external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06101966
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- Interventions
- Radiation: New-mode reduce-volume target IMRT
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 474
- Registration Number
- NCT06095154
Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
Phase 3
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 476
- Registration Number
- NCT06095167
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: CVL218
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06078670
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Phase 2
Not yet recruiting
- Conditions
- Endometrial CancerEndometrial Adenocarcinoma
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06066216
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
Not Applicable
Recruiting
- Conditions
- Stage IIIA Hepatocellular Carcinoma
- Interventions
- Combination Product: Radiotherapy combined with TKI and Anti-PD-1 Antibody
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06061445
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Not yet recruiting
- Conditions
- Cervix Carcinoma
- Interventions
- Other: no intervention
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06039982
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath